Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain.
BACKGROUND
Tapentadol is a new, centrally active analgesic agent with two modes of action--mu opioid receptor agonism and norepinephrine reuptake inhibition--and the immediate-release (IR) formulation is approved in the US for the relief of moderate to severe acute pain. The aims of this analysis were to develop a population pharmacokinetic model to facilitate the understanding of the pharmacokinetics of tapentadol IR in healthy subjects and patients following single and multiple dosing, and to identify covariates that might explain variability in exposure following oral administration.


METHODS
The analysis included pooled data from 11,385 serum pharmacokinetic samples from 1827 healthy subjects and patients with moderate to severe pain. Population pharmacokinetic modelling was conducted using nonlinear mixed-effects modelling (NONMEM) software to estimate population pharmacokinetic parameters and the influence of the subjects' demographic characteristics, clinical laboratory chemistry values and disease status on these parameters. Simulations were performed to assess the clinical relevance of the covariate effects on tapentadol exposure.


RESULTS
A two-compartment model with zero-order release followed by first-order absorption and first-order elimination best described the pharmacokinetics of tapentadol IR following oral administration. The interindividual variability (coefficient of variation) in apparent oral clearance (CL/F) and the apparent central volume of distribution after oral administration were 30% and 29%, respectively. An additive error model was used to describe the residual variability in the log-transformed data, and the standard deviation values were 0.308 and 0.314 for intensively and sparsely sampled data, respectively. Covariate analysis showed that sex, age, bodyweight, race, body fat, hepatic function (using total bilirubin and total protein as surrogate markers), health status and creatinine clearance were statistically significant factors influencing the pharmacokinetics of tapentadol. Total bilirubin was a particularly important factor that influenced CL/F, which decreased by more than 60% in subjects with total bilirubin greater than 50 micromol/L.


CONCLUSIONS
The population pharmacokinetic model for tapentadol IR identified the relationship between pharmacokinetic parameters and a wide range of covariates. The simulations of tapentadol exposure with identified, statistically significant covariates demonstrated that only hepatic function (as characterized by total bilirubin and total protein) may be considered a clinically relevant factor that warrants dose adjustment. None of the other covariates are of clinical relevance, nor do they necessitate dose adjustment.
Xu
Xu Steven
XS
Advanced PK-PD Modeling and Simulation, Clinical Pharmacology, Johnson & Johnson Pharmaceutical R&D, Raritan, New Jersey 08869, USA. sxu26@its.jnj.com
Smit
Johan W
JW
Lin
Rachel
R
Stuyckens
Kim
K
Terlinden
Rolf
R
Nandy
Partha
P
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000700:Analgesics / Q000008:administration & dosage / Q000493:pharmacokinetics*; D019540:Area Under Curve; D001682:Biological Availability; D003198:Computer Simulation; D018450:Disease Progression; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D009010:Monte Carlo Method; D010146:Pain / Q000188:drug therapy*; D010636:Phenols / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000077432:Tapentadol; D055815:Young Adult
D000700:Analgesics; D010636:Phenols; D000077432:Tapentadol
Clin Pharmacokinet. 1984 Jan;9 Suppl 1:18-26
6705423
J Pharmacol Exp Ther. 2007 Oct;323(1):265-76
17656655
Curr Med Res Opin. 2008 Nov;24(11):3185-96
18851776
Br J Clin Pharmacol. 1999 Jun;47(6):637-43
10383541
J Pharmacokinet Pharmacodyn. 2008 Feb;35(1):101-16
17963024
Clin Pharmacol Ther. 2009 Jan;85(1):23; author reply 24
18288084
Nephron. 1976;16(1):31-41
1244564
Eur J Clin Pharmacol. 1974;7(1):31-7
4852619
J Pharmacokinet Biopharm. 1996 Apr;24(2):153-72
8875345
J Pharmacokinet Pharmacodyn. 2008 Aug;35(4):401-21
18686017
Eur J Pharm Sci. 2000;10(4):275-84
10838017
Anesth Analg. 2008 Dec;107(6):2048-55
19020157
J Pharmacokinet Biopharm. 1981 Aug;9(4):503-12
7310648
Clin Ther. 2009 Feb;31(2):260-71
19302899
J Clin Oncol. 2007 Oct 20;25(30):4707-13
17947717
Clin Pharmacol Ther. 2007 Nov;82(5):505-8
17952107
Comput Methods Programs Biomed. 1999 Jan;58(1):51-64
10195646
Br J Nutr. 1991 Mar;65(2):105-14
2043597
Am J Health Syst Pharm. 2009 Jan 1;66(1):8
19106337
Br J Hosp Med (Lond). 2008 Sep;69(9):499
18819294
Eur J Drug Metab Pharmacokinet. 2007 Jul-Sep;32(3):163-9
18062408
Antimicrob Agents Chemother. 1998 May;42(5):1098-104
9593134
Trends Pharmacol Sci. 1991 Mar;12(3):96-101
2053193